Our look is new. Our purpose is the same. Learn more about our brand evolution.
This is a continuation of our Q&A session with Rabi Tawil, MD, co-director of the MDA Neuromuscular Disease Clinic at the University of Rochester, New York, and lead author of […]
The cause of facioscapulohumeral muscular dystrophy (FSHD) is thought to center on DUX4, a gene that normally is silent in adult skeletal muscle. When DUX4 gets “expressed,” as happens in […]
By Amy Bekier, San Diego, California On July 30, 2016, twenty-five FSHD patients, family and scientists assembled at Genea Biocells in La Jolla, California, to hear presentations by senior scientists […]
Grants approved from February 2016 cycle set new record. The FSH Society has committed $648,774 in funding to five research projects that aim to break new ground in the search […]
From BusinessWire CAMBRIDGE, Mass.–(BUSINESS WIRE)–Third Rock Ventures, LLC today announced the launch of Fulcrum Therapeutics, a company focused on unlocking gene control mechanisms to develop small molecule therapies. Fulcrum will […]
